ClinicalTrials.gg
CompletedNCT01763905GAUSS-2Updated Jul 20, 2020Results posted

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

A Phase 3 interventional study of Evolocumab and Placebo to Evolocumab in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-20.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
11th of 21
307 · median 307
Started
2013
with 6 others
Phase 3
12 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 11th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 5th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors).

03

Conditions studied

  • Hyperlipidemia

Keywords

  • High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 80 years of age
  • Not on a statin or on a low dose statin with stable dose for at least 4 weeks
  • History of intolerance to at least 2 statins
  • Subject not at LDL-C goal
  • Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks.
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes, poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Active comparator
    Ezetimibe (Q2W)

    Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.

    Drug: Placebo to Evolocumab · Drug: Ezetimibe

  • Active comparator
    Ezetimibe (QM)

    Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.

    Drug: Placebo to Evolocumab · Drug: Ezetimibe

  • Experimental
    Evolocumab Q2W

    Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

    Biological: Evolocumab · Drug: Placebo to Ezetimibe

  • Experimental
    Evolocumab QM

    Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

    Biological: Evolocumab · Drug: Placebo to Ezetimibe

Interventions

  • BiologicalEvolocumab

    Subcutaneous injection

    Also known as: AMG 145, Repatha

  • DrugPlacebo to Evolocumab

    Subcutaneous injection

  • Tablet for oral administration

    Also known as: Zetia

  • DrugPlacebo to Ezetimibe

    Tablet for oral administration

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

Secondary outcomes

  1. Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  2. Change From Baseline in LDL-C at Week 12

    Time frame: Baseline and Week 12

  3. Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)

    Time frame: Weeks 10 and 12

  4. Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12

    Time frame: Week 12

  5. Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  6. Percent Change From Baseline in Non-HDL-C at Week 12

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  8. Percent Change From Baseline in Apolipoprotein B at Week 12

    Time frame: Baseline and Week 12

  9. Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  10. Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12

    Time frame: Baseline and Week 12

  11. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  12. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

    Time frame: Baseline and Week 12

  13. Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  14. Percent Change From Baseline in Lipoprotein (a) at Week 12

    Time frame: Baseline and Week 12

  15. Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  16. Percent Change From Baseline in Triglycerides at Week 12

    Time frame: Baseline and Week 12

  17. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  18. Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Time frame: Baseline and Week 12

  19. Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12

    Time frame: Baseline and Weeks 10 and 12

  20. Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Dec 22, 2015

Participant flow

Men and women ≥ 18 to ≤ 80 years of age who have tried at least 2 statins and were unable to tolerate any dose or increase in statin dose due to muscle-related side effects were eligible for this study. The first participant was enrolled on 24 January 2013 and the last participant enrolled on 29 August 2013.

Participant flow — Overall Study
MilestoneEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Started5151103102
Completed455094101
Not completed6191
Withdrew: Withdrawal by subject1101
Withdrew: Decision by sponsor5080
Withdrew: Lost to follow-up0010

Outcome measures

PrimaryPercent Change From Baseline in LDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at Week 12-18.08 ± 2.52-15.05 ± 2.13-56.14 ± 1.91-52.60 ± 1.58
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -38.06 · 95% CI -43.73 to -32.99The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -37.55 · 95% CI -42.16 to -32.94The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
mg/dLEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-39.1 ± 5.1-33.0 ± 4.5-105.4 ± 3.9-103.6 ± 3.4
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -66.3 · 95% CI -77.9 to -54.7The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -70.6 · 95% CI -80.5 to -60.7The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryChange From Baseline in LDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Change From Baseline in LDL-C at Week 12-36.2 ± 5.4-30.2 ± 4.7-106.0 ± 4.1-99.0 ± 3.5
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -69.7 · 95% CI -82.0 to -57.5The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -68.8 · 95% CI -79.2 to -58.4The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
Time frame:
Weeks 10 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
percentage of participantsEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)2.0 (0.4 to 10.5)0.0 (0.0 to 7.3)45.5 (36.2 to 55.2)42.0 (32.8 to 51.8)
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 43.5 · 95% CI 30.9 to 53.4Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.
  • Ezetimibe (QM) vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Treatment difference: 42.0 · 95% CI 30.3 to 51.8Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.
SecondaryPercentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
percentage of participantsEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 122.0 (0.4 to 10.7)0.0 (0.0 to 7.9)50.0 (40.3 to 59.7)37.5 (28.5 to 47.5)
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05) · Treatment difference: 48.0 · 95% CI 35.0 to 57.8Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.
  • Ezetimibe (QM) vs Evolocumab QM · Cochran-Mantel-Haenszel · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05) · Treatment difference: 37.5 · 95% CI 25.5 to 47.5Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.
SecondaryPercent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12-17.18 ± 2.15-14.54 ± 1.86-48.72 ± 1.64-49.13 ± 1.40
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -31.53 · 95% CI -36.34 to -26.73The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.58 · 95% CI -38.63 to -30.54The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Non-HDL-C at Week 12-16.53 ± 2.30-13.16 ± 1.93-48.62 ± 1.74-46.15 ± 1.43
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -32.09 · 95% CI -37.28 to -26.90The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -32.99 · 95% CI -37.19 to -28.79The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12-13.67 ± 2.15-11.02 ± 2.21-45.88 ± 1.68-46.01 ± 1.65
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -32.20 · 95% CI -36.92 to -27.49The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.99 · 95% CI -39.59 to -30.39The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B at Week 12-12.95 ± 2.32-9.97 ± 2.34-45.81 ± 1.79-43.07 ± 1.73
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -32.86 · 95% CI -38.04 to -27.68The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -33.10 · 95% CI -38.04 to -28.17The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12-13.44 ± 2.14-11.20 ± 2.16-40.83 ± 1.65-41.14 ± 1.62
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -27.39 · 95% CI -32.11 to -22.67The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -29.94 · 95% CI -34.72 to -25.17The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12-14.13 ± 2.30-9.92 ± 2.34-40.42 ± 1.75-38.57 ± 1.73
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -26.28 · 95% CI -31.42 to -21.15The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -28.66 · 95% CI -33.88 to -23.43The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12-13.00 ± 2.27-11.94 ± 2.56-47.86 ± 1.77-48.31 ± 1.92
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.86 · 95% CI -39.84 to -29.88The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -36.37 · 95% CI -41.73 to -31.01The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12-13.14 ± 2.47-11.37 ± 2.71-47.66 ± 1.90-45.51 ± 2.01
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.53 · 95% CI -40.05 to -29.00The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.13 · 95% CI -39.87 to -28.39The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12-2.30 ± 3.361.55 ± 4.01-26.20 ± 2.64-23.72 ± 2.97
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -23.90 · 95% CI -31.27 to -16.54The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -25.26 · 95% CI -33.75 to -16.77The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Lipoprotein (a) at Week 12-1.74 ± 3.585.81 ± 5.10-27.03 ± 2.78-22.07 ± 3.66
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -25.29 · 95% CI -33.26 to -17.33The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -27.88 · 95% CI -39.21 to -16.56The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12-3.74 ± 3.88-0.32 ± 4.65-6.32 ± 2.94-6.73 ± 3.44
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.97 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -2.59 · 95% CI -11.38 to 6.20The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.33 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -6.42 · 95% CI -16.55 to 3.71The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Triglycerides at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Triglycerides at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Triglycerides at Week 12-5.47 ± 4.252.16 ± 5.52-3.88 ± 3.18-2.53 ± 3.98
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.97 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 1.58 · 95% CI -8.14 to 11.31The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.33 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -4.69 · 95% CI -17.04 to 7.67The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 120.33 ± 1.981.44 ± 2.035.48 ± 1.517.18 ± 1.51
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.068 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 5.15 · 95% CI 0.74 to 9.56The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.13 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 5.74 · 95% CI 1.23 to 10.24The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 121.77 ± 2.221.64 ± 2.225.34 ± 1.676.47 ± 1.63
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.068 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 3.57 · 95% CI -1.49 to 8.63The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.13 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 4.83 · 95% CI -0.16 to 9.81The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12-5.76 ± 3.80-2.93 ± 4.41-7.60 ± 2.89-6.46 ± 3.21
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.97 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -1.84 · 95% CI -10.43 to 6.75The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.33 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -3.53 · 95% CI -13.12 to 6.06The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
SecondaryPercent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12-5.49 ± 4.05-2.25 ± 5.11-6.16 ± 3.08-2.18 ± 3.60
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = 0.97 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -0.67 · 95% CI -9.96 to 8.61The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = 0.33 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: 0.08 · 95% CI -11.24 to 11.39The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
PrimaryPercent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame:
Baseline and Weeks 10 and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
percent changeEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12-19.21 ± 2.40-16.62 ± 2.03-56.11 ± 1.83-55.31 ± 1.53
Statistical analysis
  • Ezetimibe (Q2W) vs Evolocumab Q2W · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -36.90 · 95% CI -42.26 to -31.55The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.
  • Ezetimibe (QM) vs Evolocumab QM · Repeated measures linear effects model · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -38.69 · 95% CI -43.06 to -34.22The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.

Adverse events

Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe (Q2W)—1/51 (2%)20/51 (39.2%)
Ezetimibe (QM)—3/51 (5.9%)29/51 (56.9%)
Evolocumab Q2W—5/103 (4.9%)28/103 (27.2%)
Evolocumab QM—1/102 (1%)42/102 (41.2%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
Gastrointestinal motility disorderGastrointestinal disorders1/510/510/1030/102
Inguinal herniaGastrointestinal disorders0/511/510/1030/102
Kidney infectionInfections and infestations0/511/510/1030/102
Spinal decompressionSurgical and medical procedures0/511/510/1030/102
Cartilage graftSurgical and medical procedures0/510/510/1031/102
OsteotomySurgical and medical procedures0/510/510/1031/102
Hepatic enzyme increasedInvestigations0/510/511/1030/102
Back painMusculoskeletal and connective tissue disorders0/510/511/1030/102
Bladder transitional cell carcinoma stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/510/511/1030/102
LipomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/510/511/1030/102
Most frequent other events
Showing 10 of 12
Most frequent other events
EventEzetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QM
MyalgiaMusculoskeletal and connective tissue disorders7/5111/517/1039/102
FatigueGeneral disorders4/516/513/1036/102
Pain in extremityMusculoskeletal and connective tissue disorders0/511/512/10312/102
HeadacheNervous system disorders3/516/514/10312/102
NauseaGastrointestinal disorders2/515/513/1036/102
DiarrhoeaGastrointestinal disorders3/514/513/1032/102
Muscle spasmsMusculoskeletal and connective tissue disorders3/511/515/1038/102
ParaesthesiaNervous system disorders1/514/510/1032/102
Injection site erythemaGeneral disorders0/513/512/1032/102
InfluenzaInfections and infestations3/510/511/1030/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
Mean61.7 ± 10.160.2 ± 8.760.5 ± 9.762.9 ± 10.261.5 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
Female27224646141
Male24295756166
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
American Indian or Alaska Native00000
Asian135110
Black or African American01337
Native Hawaiian or Other Pacific Islander00101
White49469498287
Other11002
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
Hispanic or Latino12317
Not Hispanic or Latino5049100101300
Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level
Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level(participants)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
< 180 mg/dL26265252156
≥ 180 mg/dL25255150151
Stratification Factor: Baseline Statin Use
Stratification Factor: Baseline Statin Use(participants)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
No41428482249
Yes109192058
LDL-C Concentration
LDL-C Concentration(mg/dL)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
Mean194.7 ± 63.8195.2 ± 51.8192.0 ± 57.0192.2 ± 61.2193.1 ± 58.5
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)Ezetimibe (Q2W)Ezetimibe (QM)Evolocumab Q2WEvolocumab QMTotal
Mean231.4 ± 66.0232.9 ± 57.0227.9 ± 56.6222.1 ± 63.2227.4 ± 60.4

7 further baseline measures are reported on the registry.

08

Study locations

58 sites
  • Research Site
    Carmichael, California 95608, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Traverse City, Michigan 49684, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89117, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Akron, Ohio 44311, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Norman, Oklahoma 73069, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Camperdown, New South Wales 2015, Australia
  • Research Site
    Milton, Queensland 4064, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Perth, Western Australia 6000, Australia
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    La Louvière, 7100, Belgium
  • Research Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Research Site
    Lachine, Quebec H8S 2E4, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Lille Cedex, 59037, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Vénissieux, 69200, France
  • Research Site
    Bad Krozingen, 79189, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Heppenheim, 64646, Germany
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    New Territories, Hong Kong
  • Research Site
    Alkmaar, 1815 JD, Netherlands
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Lodz, 90-368, Poland
  • Research Site
    Warszawa, 04-730, Poland
  • Research Site
    Midrand, Gauteng 1685, South Africa
  • Research Site
    Observatory, Western Cape 7925, South Africa
  • Research Site
    Somerset West, Western Cape 7130, South Africa
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    Zaragoza, Aragón 50009, Spain
  • Research Site
    Reus, Cataluña 43204, Spain
  • Research Site
    Lugano, 6900, Switzerland
  • Research Site
    Reinach, 4153, Switzerland
  • Research Site
    Liverpool, L22 0LG, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
  • Research Site
    Telford, TF1 6TF, United Kingdom
  • Research Site
    West Bromwich, B71 4HJ, United Kingdom
09

References and documents

Publications

  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7. PubMed 29736889 ↗
  • Cho L, Dent R, Stroes ESG, Stein EA, Sullivan D, Ruzza A, Flower A, Somaratne R, Rosenson RS. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther. 2018 Aug;32(4):365-372. doi: 10.1007/s10557-018-6817-7. PubMed 30073585 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16. PubMed 29768954 ↗
  • Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014 Mar;37(3):131-9. doi: 10.1002/clc.22248. Epub 2014 Jan 29. PubMed 24477778 ↗
  • Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2541-2548. doi: 10.1016/j.jacc.2014.03.019. Epub 2014 Mar 30. PubMed 24694531 ↗
  • Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932. PubMed 30755061 ↗
  • Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21. PubMed 30120772 ↗
  • Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. PubMed 32114889 ↗
  • Koren MJ, Jones PH, Robinson JG, Sullivan D, Cho L, Hucko T, Lopez JAG, Fleishman AN, Somaratne R, Stroes E. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiol Ther. 2020 Dec;9(2):447-465. doi: 10.1007/s40119-020-00181-8. Epub 2020 Jun 20. PubMed 32564340 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Nov 2013, 9 months.

Results were first posted in Dec 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2013
First posted
Jan 9, 2013
StartActual
Jan 24, 2013
Primary completionActual
Nov 19, 2013
CompletionActual
Nov 19, 2013
Results delay requested
May 2, 2014
Results first posted
Dec 22, 2015
Last update
Jul 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01763905
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Jan 24, 2013
Primary completion
Nov 19, 2013
Completion
Nov 19, 2013
Results posted
Dec 22, 2015
Last update
Jul 20, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion